BACKGROUND/RATIONALE: Adherence to cholinesterase inhibitor (ChEI) is associated with treatment effectiveness in the treatment of @entity195 ( @entity195 ). We investigated the clinical adherence to @entity8124 in Taiwan. METHODS: This was a retrospective study. @entity1 treated with @entity8124 were recruited from Kaohsiung Medical University Hospital and Kaohsiung Municipal Ta-Tung Hospital from February 2004 to April 2013. We analyzed their treatment duration in months. RESULTS: A total of 273 @entity1 were included in our analysis. Sixty-seven @entity1 withdrew from @entity8124 treatment with mean treatment duration of 28.0    25.9 months. Better initial scores on the Mini-Mental Status Examination (P = .007), Cognitive Abilities Screening Instrument (P = .003), and the Clinical Dementia Rating Scale (CDR) Sum of Boxes (P = .011) were positively associated with clinical adherence. The clinical adherent rate was higher in the CDR-0.5 group than in the @entity8897 .0 group with significant difference. CONCLUSION: Although there are some limitations in our study, these findings indicate that early intervention with ChEI in @entity1 with @entity195 should be emphasized and may lead to a better clinical adherence.

Clinical Compliance of XXXX in Treating @entity195 in Taiwan.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil'] @entity8897 :: ('1039', 'Gene') :: ['CDR-2'] @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]
@entity8124 :: (MESH:C076946,Chemical) :: ['Donepezil']
